Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review

Haiyun Xu, Xiaoyin ZhuangThe Mental Health Center, Shantou University Medical College, Shantou, People’s Republic of ChinaAbstract: The atypical antipsychotics (AAPs) have been used as first-line drugs in psychiatric practice for a wide range of psychotic disorders, including schizophrenia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xu H, Zhuang X
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Antipsychotics MetS NAFLD schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a148091528934487848621f979d8f726
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a148091528934487848621f979d8f726
record_format	dspace
spelling	oai:doaj.org-article:a148091528934487848621f979d8f7262021-12-02T03:18:44ZAtypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review1178-2021https://doaj.org/article/a148091528934487848621f979d8f7262019-07-01T00:00:00Zhttps://www.dovepress.com/atypical-antipsychotics-induced-metabolic-syndrome-and-nonalcoholic-fa-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Haiyun Xu, Xiaoyin ZhuangThe Mental Health Center, Shantou University Medical College, Shantou, People’s Republic of ChinaAbstract: The atypical antipsychotics (AAPs) have been used as first-line drugs in psychiatric practice for a wide range of psychotic disorders, including schizophrenia and bipolar mania. While effectively exerting therapeutic effects on positive and negative symptoms, as well as cognitive impairments in schizophrenia patients, these drugs are less likely to induce extrapyramidal symptoms compared to typical antipsychotics. However, the increasing application of them has raised questions on their tolerability and adverse effects over the endocrine, metabolic, and cardiovascular axes. Specifically, AAPs are associated to different extents, with weight gain, metabolic syndrome (MetS), and nonalcoholic fatty liver disease (NAFLD). This article summarized clinical evidence showing the metabolic side effects of AAPs in patients with schizophrenia, and experimental evidence of AAPs-induced metabolic side effects observed in animals and cell culture studies. In addition, it discussed potential mechanisms involved in the APPs-induced MetS and NAFLD.Keywords: antipsychotics, MetS, NAFLD, schizophreniaXu HZhuang XDove Medical PressarticleAntipsychoticsMetSNAFLDschizophreniaNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 2087-2099 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Antipsychotics MetS NAFLD schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Antipsychotics MetS NAFLD schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Xu H Zhuang X Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
description	Haiyun Xu, Xiaoyin ZhuangThe Mental Health Center, Shantou University Medical College, Shantou, People’s Republic of ChinaAbstract: The atypical antipsychotics (AAPs) have been used as first-line drugs in psychiatric practice for a wide range of psychotic disorders, including schizophrenia and bipolar mania. While effectively exerting therapeutic effects on positive and negative symptoms, as well as cognitive impairments in schizophrenia patients, these drugs are less likely to induce extrapyramidal symptoms compared to typical antipsychotics. However, the increasing application of them has raised questions on their tolerability and adverse effects over the endocrine, metabolic, and cardiovascular axes. Specifically, AAPs are associated to different extents, with weight gain, metabolic syndrome (MetS), and nonalcoholic fatty liver disease (NAFLD). This article summarized clinical evidence showing the metabolic side effects of AAPs in patients with schizophrenia, and experimental evidence of AAPs-induced metabolic side effects observed in animals and cell culture studies. In addition, it discussed potential mechanisms involved in the APPs-induced MetS and NAFLD.Keywords: antipsychotics, MetS, NAFLD, schizophrenia
format	article
author	Xu H Zhuang X
author_facet	Xu H Zhuang X
author_sort	Xu H
title	Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
title_short	Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
title_full	Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
title_fullStr	Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
title_full_unstemmed	Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
title_sort	atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/a148091528934487848621f979d8f726
work_keys_str_mv	AT xuh atypicalantipsychoticsinducedmetabolicsyndromeandnonalcoholicfattyliverdiseaseacriticalreview AT zhuangx atypicalantipsychoticsinducedmetabolicsyndromeandnonalcoholicfattyliverdiseaseacriticalreview
_version_	1718401812269105152

Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review

Ejemplares similares